ANSWER: D

Rationale:

This question asked you to integrate the bilateral symmetric clinical presentation and normal DAT scan result to determine the correct diagnosis and management. Option D is correct. Two findings together confirm drug-induced parkinsonism from D2 receptor blockade: bilateral symmetric onset — in contrast to the characteristically asymmetric presentation of idiopathic PD — and a normal DAT scan, which confirms that nigrostriatal dopaminergic nerve terminals are structurally intact. The normal DAT scan is the critical discriminating result: DAT binding is reduced only when presynaptic dopaminergic terminals are physically lost through neurodegeneration, as in idiopathic PD. In drug-induced parkinsonism caused by a D2 receptor antagonist such as olanzapine, the terminals are intact and the transporter is present — hence normal binding. Adding levodopa in this context is pharmacologically futile because the dopamine receptor is pharmacologically occupied by olanzapine; the dopamine produced from levodopa cannot access a blocked receptor. The correct strategy is reduction of olanzapine dose or substitution with a lower-D2-affinity antipsychotic such as quetiapine or clozapine.

• Option A: Option A is incorrect. A normal DAT scan in the context of an antipsychotic-treated patient does not indicate inadequate dopamine production requiring supplementation; it indicates postsynaptic D2 blockade with structurally intact presynaptic neurons. Levodopa cannot act at a receptor occupied by olanzapine, regardless of the DAT result.
• Option B: Option B is incorrect. The normal DAT scan and the bilateral symmetric presentation are consistent with D2 receptor blockade by olanzapine, not with a VMAT2 depletion mechanism; VMAT2 inhibitors such as tetrabenazine or reserpine are a separate class of causative agents that olanzapine does not resemble pharmacologically.
• Option C: Option C is incorrect. A normal DAT scan in DIP reflects postsynaptic receptor blockade, not a presynaptic depletion of vesicular dopamine stores; the mechanism does not involve inadequate vesicular dopamine, and high-dose levodopa does not address receptor occupancy by an antipsychotic.
• Option E: Option E is incorrect. A normal DAT scan does not rule out drug-induced parkinsonism; it is entirely consistent with — and in fact expected in — DIP caused by D2 receptor antagonism, precisely because the nigrostriatal pathway is structurally intact in this setting.

ANSWER: A

Rationale:

This question asked you to select the management plan that correctly addresses dopaminergic continuity, antiemetic selection, and delirium management simultaneously in a patient with advanced Parkinson's disease and postoperative ileus. Option A is correct across all three decisions. First, rotigotine transdermal patch is the established perioperative bridging strategy for PD patients who cannot take oral medications; it maintains basal dopaminergic tone through the skin without requiring gastrointestinal access, preventing the acute akinesia and aspiration risk that follow levodopa withdrawal. Second, ondansetron is the antiemetic of choice in PD because it is a 5-HT3 receptor antagonist with no dopamine receptor blocking activity, carrying no risk of motor worsening. Third, low-dose quetiapine (12.5 to 25 mg) is appropriate for agitation or delirium in PD patients because of its very low D2 receptor affinity at these doses, avoiding the severe motor deterioration that haloperidol would cause.

• Option B: Option B is incorrect on all three counts: holding all antiparkinson medications risks acute akinesia and aspiration; metoclopramide is a D2 receptor antagonist contraindicated at any dose in PD; and haloperidol is a potent D2 blocker that will severely worsen motor function.
• Option C: Option C is incorrect: nasogastric tube delivery of levodopa is logistically complex and non-standard during ileus; prochlorperazine is a phenothiazine with potent D2 blocking activity contraindicated in PD; and while lorazepam carries no specific dopaminergic risk, it is not preferred for delirium management in older PD patients due to sedation and fall risk.
• Option D: Option D is incorrect: while apomorphine subcutaneous infusion is a legitimate device-based antiparkinson therapy, it is not the standard perioperative bridging strategy and requires specialist setup; domperidone is not available in the United States; and risperidone has significant D2 receptor blocking activity that will worsen parkinsonism.
• Option E: Option E is incorrect: the nil-by-mouth order exists for surgical safety reasons and cannot be routinely overridden for oral medications — rotigotine transdermal is the correct solution for maintaining dopaminergic therapy without oral intake; and pimavanserin is appropriate for PD psychosis but is not typically used for acute postoperative agitation, where quetiapine is the more established rapid-onset option.

ANSWER: C

Rationale:

This question asked you to apply the evidence-based hierarchy of antiparkinson drug safety in pregnancy to restructure a three-drug regimen. Option C is correct and reflects all three components of the appropriate decision. Levodopa/carbidopa is continued at the lowest effective dose: it has the longest and most substantial human pregnancy experience of any antiparkinson agent, case series have not demonstrated a consistent teratogenic signal at therapeutic doses, and untreated PD with severe motor impairment carries its own risks of falls and aspiration during pregnancy. Pramipexole is discontinued: as a non-ergot dopamine agonist used predominantly in older PD populations, it has limited human pregnancy data and is classified based on preclinical toxicology findings; it is generally avoided in the first trimester when organogenesis is occurring. Rasagiline is discontinued: MAO-B inhibitors have insufficient human pregnancy safety data, and the theoretical risks — including effects on serotonin and catecholamine metabolism during fetal development — support discontinuation when an alternative exists.

• Option A: Option A is incorrect: discontinuing all antiparkinson therapy in a patient with established PD and motor symptoms severe enough to require a three-drug regimen exposes her to serious risk of falls, aspiration, and functional disability during pregnancy; levodopa should be continued when motor symptoms are significant.
• Option B: Option B is incorrect: continuing pramipexole and rasagiline without reassessment ignores the meaningful difference in pregnancy safety profiles between levodopa and the agonist/MAO-B inhibitor classes; the risk-benefit calculation does not support maintaining all three agents unchanged.
• Option D: Option D is incorrect: the hierarchy of pregnancy safety is inverted — levodopa has more human pregnancy data and a better-established safety profile than pramipexole; substituting the better-characterized agent for one with limited data increases rather than decreases fetal risk.
• Option E: Option E is incorrect: continuing rasagiline and discontinuing levodopa reverses the established pregnancy safety hierarchy; MAO-B inhibitors have no established neuroprotective benefit in human pregnancy and have no safety data to support preference over levodopa; the animal skeletal malformation data for levodopa has not translated to a consistent human teratogenic signal at therapeutic doses.

ANSWER: E

Rationale:

This question asked you to identify the dual pharmacodynamic mechanism underlying the meperidine-rasagiline interaction and the specific property of meperidine responsible. Option E is correct. Meperidine is atypical among opioid analgesics in possessing serotonin reuptake inhibiting properties in addition to its mu-opioid receptor agonist activity. When serotonin reuptake is blocked, synaptic serotonin concentrations rise. Rasagiline inhibits MAO-B, an enzyme that participates in serotonin degradation; with MAO-B inhibited, serotonin that escapes reuptake is less efficiently broken down, further elevating synaptic serotonin. The combination of impaired serotonin reuptake and impaired serotonin catabolism produces toxic serotonergic excess — serotonin syndrome — characterized by the triad of hyperthermia, neuromuscular abnormalities (rigidity, clonus, hyperreflexia), and autonomic instability (tachycardia, diaphoresis, agitation). This interaction is absolute in its contraindication status and is listed among the most dangerous drug interactions in antiparkinson pharmacology. Safe opioid alternatives — morphine, oxycodone, fentanyl — lack the serotonin reuptake inhibiting property and can be used instead.

• Option A: Option A is incorrect. Meperidine does not meaningfully inhibit CYP1A2, and pharmacokinetic elevation of rasagiline levels is not the mechanism of this interaction; the interaction is pharmacodynamic through serotonergic pathways, not through increased rasagiline drug exposure.
• Option B: Option B is incorrect. While rasagiline does cause some catecholamine accumulation through MAO inhibition, the clinical syndrome of serotonin syndrome is serotonergic, not primarily noradrenergic; noradrenergic storm is not the established mechanism of this interaction, and meperidine's locus coeruleus activation does not constitute the primary pharmacological basis.
• Option C: Option C is incorrect. Meperidine does not displace rasagiline from MAO-B binding sites; meperidine is not an MAO substrate or competitor in a way that reverses MAO-B inhibition, and rebound dopamine oxidation is not an established mechanism for this interaction.
• Option D: Option D is incorrect. While normeperidine accumulation is a recognized toxicity of meperidine in renal impairment, MAO-B inhibition does not significantly affect normeperidine metabolism, which is primarily hepatic; the syndrome described here is serotonin syndrome, not normeperidine toxicity, which presents primarily with seizures and excitatory CNS effects rather than the full serotonergic triad.

ANSWER: B

Rationale:

This question asked you to identify the clinically decisive pharmacological distinction between tolcapone and entacapone. Option B is correct. Both tolcapone and entacapone are COMT inhibitors that extend levodopa efficacy by reducing peripheral levodopa degradation. Their mechanism of action is the same and their antiparkinson efficacy is broadly comparable. The clinically decisive difference is the safety profile: tolcapone is associated with rare but potentially fatal hepatotoxicity, including cases of fulminant hepatic failure that have resulted in death. This led to a black-box warning requiring liver function testing at baseline and at regular intervals during therapy. Patients must also be counseled on hepatotoxicity symptoms. Entacapone does not carry this hepatotoxicity risk and requires no liver function monitoring. Because of tolcapone's additional safety burden, entacapone is typically the preferred COMT inhibitor for most patients, with tolcapone reserved for those who do not respond to or cannot tolerate entacapone. When tolcapone is used, the prescriber takes on a mandatory monitoring commitment that does not apply with entacapone.

• Option A: Option A is incorrect. The peripheral versus central COMT inhibition distinction is partially reversed: entacapone acts predominantly peripherally with limited CNS penetration, while tolcapone does cross the blood-brain barrier and inhibits both peripheral and central COMT — but this pharmacokinetic distinction, while real, is not the clinically decisive factor that governs agent selection; the hepatotoxicity risk of tolcapone is the defining concern.
• Option C: Option C is incorrect. Tolcapone is primarily eliminated by hepatic metabolism, not renal excretion; renal dose adjustment is not the distinguishing clinical requirement between these agents.
• Option D: Option D is incorrect. Both tolcapone and entacapone are reversible COMT inhibitors; neither is irreversible, and the distinction between them is not based on reversibility or dosing frequency differences driven by mechanism type.
• Option E: Option E is incorrect. Tolcapone is not preferred in older adults for peripheral selectivity reasons; in fact, tolcapone's ability to cross the blood-brain barrier and its hepatotoxicity risk make it less straightforwardly preferable in older patients, and entacapone is generally the first-choice COMT inhibitor regardless of age.

ANSWER: D

Rationale:

This question asked you to integrate the pharmacological mechanisms of three different agents to explain a cumulative fall risk in an older patient with Parkinson's disease. Option D is correct. Each agent contributes a distinct pharmacological mechanism to the overall fall risk, and together they act additively. Levodopa causes orthostatic hypotension through peripheral dopaminergic vasodilation — dopamine receptors in peripheral vasculature produce vasodilation that, in the absence of adequate autonomic compensatory reflexes (already impaired in PD), results in blood pressure drops upon standing. Quetiapine contributes both sedation — reducing alertness and reaction time — and alpha-1 adrenergic receptor blockade, which further impairs the sympathetic vasoconstriction needed to maintain blood pressure during postural change. Oxybutynin, a muscarinic antagonist for bladder overactivity, adds anticholinergic burden: central muscarinic blockade impairs cognitive processing speed, attention, and reaction time, while the peripheral anticholinergic effects reduce the sweating and heart rate responses that normally compensate for positional blood pressure changes. The convergence of three independent mechanisms — vasodilation, sedation plus alpha blockade, and anticholinergic impairment — produces a cumulative fall risk substantially greater than any single agent would generate. This type of multi-drug fall risk analysis is a mandatory structured review at every clinic visit in older PD patients.

• Option A: Option A is incorrect. These three agents do not produce additive serotonergic effects through 5-HT receptor subtypes; quetiapine has serotonin receptor activity, but this is not the mechanism by which the combination increases fall risk, and oxybutynin and levodopa are not serotonergic agents.
• Option B: Option B is incorrect. Neither quetiapine nor oxybutynin inhibits MAO-B; MAO-B inhibition is the mechanism of selegiline and rasagiline. Dyskinesia from MAO-B inhibitor-levodopa interactions is not the mechanism of this patient's falls.
• Option C: Option C is incorrect. Levodopa and oxybutynin do not share the same renal excretion pathway in a clinically meaningful way that causes levodopa accumulation; this is not an established drug interaction and does not explain the patient's fall pattern.
• Option E: Option E is incorrect. Cerebellar D2 receptor suppression is not the mechanism of falls in this clinical picture; the agents listed do not share a common cerebellar dopaminergic mechanism, and ataxic gait is not the primary pharmacological concern with this regimen.

ANSWER: C

Rationale:

This question asked you to integrate the pharmacokinetic mechanism of the ciprofloxacin-rasagiline interaction with its pharmacodynamic clinical consequences. Option C is correct at both levels. Pharmacokinetically: ciprofloxacin is a potent inhibitor of CYP1A2, the primary hepatic enzyme responsible for rasagiline metabolism via N-dealkylation. Inhibiting CYP1A2 reduces rasagiline clearance, causing plasma rasagiline concentrations to rise substantially above their intended therapeutic range during the antibiotic course. Pharmacodynamically: at elevated plasma concentrations, rasagiline's MAO-B inhibitory effects are amplified, and the risk of its known dangerous drug interactions is proportionally increased. These include the potentially fatal interaction with meperidine (serotonin syndrome), interactions with serotonergic antidepressants such as SSRIs and SNRIs, and interactions with sympathomimetic agents that may produce hypertensive reactions. The prescribing information for rasagiline specifically identifies ciprofloxacin as an agent that should be used with caution or avoided, and recommends considering alternative antibiotics without CYP1A2 inhibitory activity.

• Option A: Option A is incorrect. Ciprofloxacin inhibits, not induces, CYP1A2; induction would reduce rasagiline levels, but ciprofloxacin's actual effect is inhibition, which raises rather than lowers rasagiline concentrations.
• Option B: Option B is incorrect. Ciprofloxacin does not bind to or compete at MAO-B binding sites; it does not reverse MAO-B inhibition, and its mechanism of interaction with rasagiline is entirely pharmacokinetic through CYP1A2, not pharmacodynamic at the enzyme target.
• Option D: Option D is incorrect. Rasagiline is primarily eliminated by hepatic CYP1A2-mediated metabolism, not by renal tubular excretion; urinary pH manipulation through ciprofloxacin is not an established mechanism for rasagiline accumulation, and this explanation conflates a mechanism relevant to renally-excreted basic drugs with rasagiline's actual elimination pathway.
• Option E: Option E is incorrect. P-glycoprotein inhibition at the blood-brain barrier is not an established mechanism of the ciprofloxacin-rasagiline interaction; rasagiline does cross the blood-brain barrier, but the interaction is driven by plasma concentration changes from CYP1A2 inhibition rather than altered CNS efflux transport.

ANSWER: A

Rationale:

This question asked you to integrate the persistent and worsening clinical course with the reduced DAT scan result to determine the correct diagnosis after apparent drug-induced parkinsonism. Option A is correct. In pure drug-induced parkinsonism, the nigrostriatal dopaminergic neurons are structurally intact — DAT binding should be normal. A reduced DAT scan in the context of persistent and worsening parkinsonism after the causative drug has been fully cleared indicates that dopaminergic nerve terminals have been lost through neurodegeneration, not pharmacological blockade. The most parsimonious explanation is that the prochlorperazine exposure unmasked subclinical idiopathic Parkinson's disease that was already progressing but had not yet crossed the threshold of clinical detectability. As the pharmacological D2 blockade was removed, the parkinsonism would be expected to improve if it were purely drug-induced — instead, continued worsening confirms that underlying neurodegeneration is the driver. The asymmetric DAT reduction (worse on the right) is consistent with the characteristically asymmetric pattern of idiopathic PD, further supporting this diagnosis. This patient should now be evaluated and treated as idiopathic PD.

• Option B: Option B is incorrect. Dopamine transporter expression is not permanently downregulated by D2 receptor blockade; the DAT is a presynaptic protein on structurally intact terminals, and its expression normalizes after drug clearance. A reduced DAT scan reflects structural terminal loss, not failed transporter re-expression.
• Option C: Option C is incorrect. Prochlorperazine does not cause excitotoxic destruction of nigrostriatal neurons at therapeutic doses, and drug deposits in the substantia nigra are not an established mechanism for ongoing neuronal death after drug clearance; D2 receptor blockade is pharmacologically reversible and does not produce structural neurotoxicity in this manner.
• Option D: Option D is incorrect. Differential D2 receptor density between right and left striata does not produce asymmetric DAT scan findings in drug-induced parkinsonism; DIP characteristically produces a normal DAT scan regardless of laterality. Asymmetric DAT reduction indicates asymmetric neurodegeneration, consistent with idiopathic PD.
• Option E: Option E is incorrect. Prochlorperazine does not bind to the dopamine transporter in a way that would produce false-positive DAT scan reductions; DAT tracers bind to the transporter protein on presynaptic terminals, not to D2 receptors. A prochlorperazine-related false-positive DAT result is not an established artifact, and the eight-month drug-free period makes residual drug occupation of the tracer binding site pharmacologically implausible.

ANSWER: E

Rationale:

This question asked you to link pimavanserin's receptor pharmacology precisely to its clinical suitability for PD-associated psychosis. Option E is correct and captures the complete pharmacological reasoning. Pimavanserin acts as a selective inverse agonist at serotonin 5-HT2A receptors — and to a lesser extent 5-HT2C receptors — with no clinically relevant affinity for dopamine D2, D3, histamine H1, muscarinic, or adrenergic receptors at therapeutic doses. The serotonin 5-HT2A receptor plays an important modulatory role in cortical processing of perceptual information, and inverse agonism at this receptor reduces the aberrant serotonergic signaling that contributes to psychotic symptoms including hallucinations and delusions. Because pimavanserin achieves this antipsychotic effect entirely through serotonergic rather than dopaminergic mechanisms, it does not interfere with the D2 receptor system that antiparkinson therapy depends on. This means it does not worsen the motor features of PD — the very property that makes virtually all conventional antipsychotics unsuitable or hazardous in this population. The absence of H1 receptor affinity also explains why it is less sedating than quetiapine, which has significant H1 blocking activity.

• Option A: Option A is incorrect. Pimavanserin does not block D2 receptors at any clinically meaningful affinity; characterizing it as a lower-affinity D2 blocker misrepresents its pharmacology. Its reduced sedation compared to quetiapine is due to the absence of H1 blockade, but this is a consequence of its entirely non-dopaminergic, non-histaminergic receptor profile.
• Option B: Option B is incorrect. Pimavanserin does not block D2 receptors — it has no clinically relevant D2 activity. Describing it as a dual D2/5-HT2A blocker conflates it with a class of atypical antipsychotics (such as quetiapine and clozapine) that it specifically is not, pharmacologically.
• Option C: Option C is incorrect. Pimavanserin does not activate presynaptic D2 autoreceptors; autoreceptor agonism is a property of agents such as aripiprazole at low doses, not pimavanserin, which has no dopamine receptor activity whatsoever.
• Option D: Option D is incorrect. Pimavanserin is not a D3 partial agonist; D3 partial agonism is not its mechanism of action. Its entire therapeutic rationale depends on the complete absence of dopamine receptor activity, which allows antipsychotic efficacy without motor compromise in PD.

ANSWER: B

Rationale:

This question asked you to integrate the dual-site pharmacokinetic mechanism of LNAA competition with the rationale for the protein redistribution dietary strategy. Option B is correct. Levodopa is a large neutral amino acid and depends on the LNAA transporter — specifically the LAT1 isoform — for absorption at two distinct anatomical locations. First, at the intestinal epithelium: levodopa is absorbed from the gut lumen into systemic circulation via LNAA transporters on the apical surface of enterocytes; dietary amino acids from protein digestion compete at this site, reducing both the rate and extent of levodopa absorption into plasma. Second, at the blood-brain barrier: levodopa is transported from plasma into the CNS via LNAA transporters on the luminal membrane of brain capillary endothelial cells; elevated plasma amino acid concentrations from protein digestion compete at this site, reducing levodopa delivery to the striatum even when plasma levels appear adequate. The protein redistribution diet concentrates the day's protein in the evening meal, removing the competitive amino acid load from both transport sites during the daytime hours when reliable motor function is most important — during work, driving, social activity, and physical rehabilitation.

• Option A: Option A is incorrect. Gastric acid production is not the mechanism of protein-levodopa interaction; the LNAA transporter competition at the enterocyte and blood-brain barrier is the established mechanism, and gastrin-mediated acid changes are not the pharmacological basis for meal-related levodopa wearing-off.
• Option C: Option C is incorrect. Peripheral AADC activity is not meaningfully altered by the availability of dietary amino acid substrates in a patient receiving carbidopa; carbidopa already substantially suppresses peripheral AADC, and substrate availability does not regulate the activity of the remaining uninhibited enzyme in a way that explains meal-related wearing-off.
• Option D: Option D is incorrect. COMT does not require tyrosine or phenylalanine as cofactors; its cofactor is S-adenosyl methionine (SAM), not dietary amino acids. Hepatic COMT activity is not reduced by protein restriction, and this is not the mechanism of the protein redistribution dietary strategy.
• Option E: Option E is incorrect. The protein redistribution diet is not designed to ensure that LNAA competition occurs only during pharmacological inactivity at night; the strategy specifically aims to move competitive amino acid load away from the daytime when levodopa efficacy matters most, not to time competition with pharmacological troughs.

ANSWER: C

Rationale:

This question asked you to identify the correct management strategy for dopamine agonist withdrawal syndrome. Option C is correct. Dopamine agonist withdrawal syndrome (DAWS) results from the dependence of mesolimbic reward circuitry on chronic dopaminergic agonist stimulation. When a dopamine agonist is abruptly discontinued after prolonged use, the mesolimbic system is deprived of its pharmacological dopaminergic input before it can adapt, producing a withdrawal state characterized by severe non-motor symptoms — anxiety, dysphoria, diaphoresis, fatigue, insomnia, and drug craving — that can persist for weeks to months. The correct management is reinstatement of the dopamine agonist at the previously tolerated dose, followed by a planned gradual taper over weeks to months to allow mesolimbic adaptation. If the original indication for discontinuation (impulse control disorder) remains, the taper can be structured with appropriate behavioral monitoring, but abrupt cessation should be avoided in any patient who has developed dependency.

• Option A: Option A is incorrect. Levodopa does not effectively treat dopamine agonist withdrawal syndrome; the syndrome reflects mesolimbic reward system dependence on specific dopamine agonist pharmacology, and levodopa's conversion to dopamine does not reliably replicate the receptor-level stimulation provided by the agonist, particularly at mesolimbic D3 receptors where pramipexole has preferential activity. High-dose levodopa would also risk dyskinesia and other dopaminergic adverse effects.
• Option B: Option B is incorrect. While the autonomic symptoms of DAWS (sweating, tachycardia) superficially resemble adrenergic withdrawal, the underlying mechanism is mesolimbic dopaminergic dependence, not noradrenergic hyperactivity; clonidine addresses adrenergic symptoms but does not treat the pharmacological root cause.
• Option D: Option D is incorrect. Dopamine agonist withdrawal syndrome is not an inflammatory condition mediated by microglial activation; it is a pharmacological withdrawal state from mesolimbic D2/D3 receptor dependence. Corticosteroids have no established role in its management.
• Option E: Option E is incorrect. Dopamine agonist withdrawal syndrome symptoms do not resolve within 24 hours; they can persist for weeks to months and can be severely debilitating. Pramipexole's plasma half-life of 8 to 12 hours means it clears relatively quickly, but the mesolimbic withdrawal state it leaves behind does not resolve in parallel with drug clearance.

ANSWER: A

Rationale:

This question asked you to integrate valproic acid's mechanism of action, the DAT scan result, and the partial clinical treatment response into a coherent pharmacological conclusion. Option A is correct across all three elements. Valproic acid causes parkinsonism through mitochondrial dysfunction in dopaminergic neurons — impairing their energy metabolism and thus their capacity for dopamine synthesis, storage, and release — without causing the structural loss of presynaptic terminals that would reduce DAT binding. The normal DAT scan is therefore precisely consistent with this mechanism: the terminals are present and the transporter is expressed, but neuronal function is metabolically compromised. The partial improvement after dose reduction is also mechanistically coherent: mitochondrial dysfunction is a graded, concentration-dependent, and partially reversible phenomenon; reducing valproic acid exposure allows partial mitochondrial recovery, improving neuronal function and motor symptoms. Complete resolution may not occur for two reasons: first, mitochondrial recovery may be incomplete even at reduced drug exposure; second, if the pharmacological stress on dopaminergic reserve has unmasked subclinical idiopathic PD in this patient, the residual parkinsonism reflects ongoing neurodegeneration that is independent of drug dose.

• Option B: Option B is incorrect. The assertion that complete resolution should follow full discontinuation oversimplifies the clinical reality; partial responses are common in drug-induced parkinsonism because of the unmasking phenomenon, and predicting complete resolution requires knowing whether underlying PD exists.
• Option C: Option C is incorrect. Valproic acid does not block D2 receptors; its mechanism is mitochondrial dysfunction, not postsynaptic receptor antagonism. Framing the partial improvement as progressive D2 receptor unblocking describes a mechanism that does not apply to valproate.
• Option D: Option D is incorrect. Valproic acid does not cause irreversible mitochondrial DNA damage that would produce progressive terminal loss detectable on DAT imaging; the normal DAT scan and the partial clinical improvement are inconsistent with this trajectory, and mitochondrial dysfunction from valproate is generally considered pharmacologically reversible rather than genotoxic.
• Option E: Option E is incorrect. A normal DAT scan does not exclude drug-induced parkinsonism; it is in fact the expected finding in DIP from agents that do not cause structural neuronal loss, including valproic acid. The criterion that parkinsonism-causing drugs must reduce DAT binding is pharmacologically incorrect — only drugs causing structural presynaptic terminal loss reduce DAT binding.

ANSWER: D

Rationale:

This question asked you to trace the pharmacokinetic and pharmacodynamic chain of events that produced life-threatening motor deterioration after thirty-six hours without levodopa. Option D is correct and captures the complete causal sequence. Levodopa has a plasma half-life of approximately one hour — one of the shortest half-lives of any commonly used medication for a chronic condition. After the last oral dose, plasma levodopa concentrations fall rapidly. As plasma levels decline below the threshold needed to maintain striatal dopamine synthesis, dopaminergic motor support deteriorates progressively. In a patient with advanced PD whose motor function is heavily dependent on medication, this produces akinesia — progressive motor arrest — within hours of the last dose. Over thirty-six hours, the cumulative dopaminergic deficit becomes severe enough to eliminate meaningful voluntary movement. The muscles of swallowing are equally affected; profound dysphagia develops, eliminating the ability to protect the airway and creating immediate aspiration risk. This sequence is the mechanistic basis for the perioperative imperative that levodopa must never be simply held with other oral medications — a rotigotine transdermal patch should have been applied before surgery to maintain dopaminergic continuity through the NPO period, and all antiparkinson medications should have been restarted at the earliest safe postoperative opportunity.

• Option A: Option A is incorrect. Dopamine precursor accumulation does not occur during levodopa withdrawal; when levodopa is absent, there is no substrate for AADC-mediated dopamine synthesis in the nigrostriatal pathway. Motor worsening results from dopamine deficiency, not from receptor downregulation caused by precursor excess.
• Option B: Option B is incorrect. Postoperative inflammation does not upregulate peripheral AADC activity in a clinically meaningful way; furthermore, carbidopa administered with levodopa already substantially inhibits peripheral AADC, and the scenario of trace residual gut levodopa being converted peripherally is pharmacologically implausible as an explanation for the acute deterioration at thirty-six hours.
• Option C: Option C is incorrect. General anesthesia agents do not inhibit LNAA transporters at the blood-brain barrier for 72 hours; this is not a pharmacologically established mechanism, and the deterioration in this case is directly attributable to absent oral levodopa dosing, not to a persistent anesthetic drug effect on transport proteins.
• Option E: Option E is incorrect. While postoperative ileus does reduce gut motility and could impair oral levodopa absorption, this is not the reason the NPO hold was harmful; the fundamental problem is that no levodopa was given by any route — oral or transdermal — for thirty-six hours, not that absorption was impaired for doses that were actually administered.